Ruboxistaurin mesilate hydrate for diabetic retinopathy

Stephen Schwartz, Harry W Flynn, Lloyd Paul Aiello

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Diabetic retinopathy remains a major worldwide cause of preventable blindness. The β isoform of protein kinase C (PKC) may play an important role in the pathogenesis of this disorder. Ruboxistaurin mesylate hydrate is an orally bioavailable, highly-specific inhibitor of PKC β, which has shown some efficacy in several large, multicenter, randomized clinical trials. The U.S. Food and Drug Administration issued an approvable letter for ruboxistaurin in 2006, but at this time the medication is not available for routine clinical use.

Original languageEnglish
Pages (from-to)269-274
Number of pages6
JournalDrugs of Today
Volume45
Issue number4
DOIs
StatePublished - Apr 1 2009

Fingerprint

ruboxistaurin
Diabetic Retinopathy
Protein Kinase C
Mesylates
United States Food and Drug Administration
Blindness
Protein Isoforms
Randomized Controlled Trials

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Ruboxistaurin mesilate hydrate for diabetic retinopathy. / Schwartz, Stephen; Flynn, Harry W; Aiello, Lloyd Paul.

In: Drugs of Today, Vol. 45, No. 4, 01.04.2009, p. 269-274.

Research output: Contribution to journalArticle

@article{aca44c3521214dbe8d6d93e8ea4543fa,
title = "Ruboxistaurin mesilate hydrate for diabetic retinopathy",
abstract = "Diabetic retinopathy remains a major worldwide cause of preventable blindness. The β isoform of protein kinase C (PKC) may play an important role in the pathogenesis of this disorder. Ruboxistaurin mesylate hydrate is an orally bioavailable, highly-specific inhibitor of PKC β, which has shown some efficacy in several large, multicenter, randomized clinical trials. The U.S. Food and Drug Administration issued an approvable letter for ruboxistaurin in 2006, but at this time the medication is not available for routine clinical use.",
author = "Stephen Schwartz and Flynn, {Harry W} and Aiello, {Lloyd Paul}",
year = "2009",
month = "4",
day = "1",
doi = "101358/dot20094541354195",
language = "English",
volume = "45",
pages = "269--274",
journal = "Drugs of Today",
issn = "1699-3993",
publisher = "Prous Science",
number = "4",

}

TY - JOUR

T1 - Ruboxistaurin mesilate hydrate for diabetic retinopathy

AU - Schwartz, Stephen

AU - Flynn, Harry W

AU - Aiello, Lloyd Paul

PY - 2009/4/1

Y1 - 2009/4/1

N2 - Diabetic retinopathy remains a major worldwide cause of preventable blindness. The β isoform of protein kinase C (PKC) may play an important role in the pathogenesis of this disorder. Ruboxistaurin mesylate hydrate is an orally bioavailable, highly-specific inhibitor of PKC β, which has shown some efficacy in several large, multicenter, randomized clinical trials. The U.S. Food and Drug Administration issued an approvable letter for ruboxistaurin in 2006, but at this time the medication is not available for routine clinical use.

AB - Diabetic retinopathy remains a major worldwide cause of preventable blindness. The β isoform of protein kinase C (PKC) may play an important role in the pathogenesis of this disorder. Ruboxistaurin mesylate hydrate is an orally bioavailable, highly-specific inhibitor of PKC β, which has shown some efficacy in several large, multicenter, randomized clinical trials. The U.S. Food and Drug Administration issued an approvable letter for ruboxistaurin in 2006, but at this time the medication is not available for routine clinical use.

UR - http://www.scopus.com/inward/record.url?scp=68249094043&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68249094043&partnerID=8YFLogxK

U2 - 101358/dot20094541354195

DO - 101358/dot20094541354195

M3 - Article

C2 - 19499092

AN - SCOPUS:68249094043

VL - 45

SP - 269

EP - 274

JO - Drugs of Today

JF - Drugs of Today

SN - 1699-3993

IS - 4

ER -